Dobutamine Stress CMR: Can We Predict Outcome?⁎⁎Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.  by Garot, Jérôme & O h-Ici, Darach
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 4 , N O . 2 , 2 0 1 1
© 2 0 1 1 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c m g . 2 0 1 0 . 1 2 . 0 0 5E D I T O R I A L C O M M E N T
Dobutamine Stress CMR: Can We Predict Outcome?*
Jérôme Garot, MD, PHD, Darach O h-Ici, MB, BCH
Massy, Frances
m
e
p
g
m
(
n
f
(
i
t
t
f
C
c
c
s
w
m
D
w
b
t
D
p
D
D
i
(
3
e
s
s
n
s
p
p
rDobutamine stress magnetic resonance (DSMR)
is a well-established technique that is able to
provide accurate detection of the contractile re-
serve in asynergic ischemic segments at low-dose
dobutamine, and the assessment of reversible
myocardial ischemia at high doses (1–3). The
accuracy of the technique is due to the high quality
of cardiovascular magnetic resonance (CMR) im-
ages, the spontaneous contrast between blood pool
See page 161
and the myocardium on cine sequences, and the
excellent anatomic coverage of the left ventricle
during stress procedures. Although it is slightly
longer and probably less comfortable than stress
first-pass perfusion CMR, it has been shown to be
feasible in large cohorts of patients, robust, and safe
(3). Not surprisingly, the direct comparison of
DSMR with stress perfusion CMR for the detec-
tion of significant coronary artery disease (CAD)
tends to demonstrate a slightly better specificity for
DSMR, and a slightly better sensitivity for perfu-
sion imaging techniques (2). Both DSMR and
stress perfusion imaging have shown their value for
risk stratification in patients with known or sus-
pected CAD, but data are limited either to short-
and intermediate-term follow-up and/or small sam-
ples with low event rates (4–7).
The current study by Kelle et al. (8) significantly
contributes to our knowledge on the value of
DSMR for risk stratification. The authors demon-
strate the independent prognostic value of DSMR
in a large cohort of 1,369 patients with known or
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France. The authors have reported that they have no relationships to
disclose.uspected CAD over a mean follow-up of 44  24
onths. After exclusion of patients who underwent
arly revascularization from the main analysis, the
roportion of patients with cardiac events was
reater in those with inducible wall motion abnor-
alities (WMA) on DSMR versus those without
8.0 vs. 3.1%; hazard ratio: 3.3). It is interesting to
ote that those patients with events during
ollow-up had large areas of inducible ischemia
mean, 4.4 segments). Also, those patients with
nducible WMA treated medically demonstrated a
rend to a higher cardiac event rates (8.0%) than
hose with early revascularization (5.4%). This in-
ormation correlates well with the data from the
OURAGE (Clinical Outcomes Utilizing Revas-
ularization and Aggressive Drug Evaluation) nu-
lear substudy (9) and previous single-photon emis-
ion computed tomography data (10) that patients
ith larger amounts of ischemia have higher rates of
yocardial infarction and death. Of note, a normal
SMR carries an excellent long-term prognosis,
ith an annual cardiac event rate of 1.1%, this rate
eing less during the first 3 years (0.8%). Impor-
antly, the study also confirms in a large cohort that
SMR is safe (3). Only 94 of 1,463 (6.5%) of
atients experienced arrhythmias at the time of
SMR, and there was no hard event during
SMR testing. During the study, continuous mon-
toring is required with MR-compatible equipment
electrocardiogram, heart rate, blood pressure every
min at each increase of the dose). Resuscitation
quipment must be available just outside of the MR
uite, and a dedicated room available outside of the
canner for emergency care. The reasons to termi-
ate the test include new WMA in 2 contiguous
egments, severe arrhythmias, drop of systolic blood
ressure 30 mm Hg, severe side effects, and
atient demand. Similarly, there are important
ecommendations to ensure the overall accuracy
f the technique, such as the need for a gradual
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174decrease of oral beta-blockers several days before
DSMR and a complete withdrawal at least 48 h
before. Importantly, the target heart rate (or at
least 85% of the target rate) must be reached to
provide a reliable diagnosis, and atropine should
be added when needed in the absence of contra-
indications.
The design of the study by Kelle et al. (8) is
retrospective, and treatment strategy was based on
the sole decision of the physicians, without the need
to comply with a clearly defined protocol that
included DSMR data. As a result, 352 patients had
to be excluded from the main outcome analysis due
to early revascularization procedures after DSMR.
This is a clear limitation of the study, not only
because this may impact the outcome data, but also
because the exclusion of those patients with more
extensive ischemia (number of segments with in-
ducible WMA on DSMR, 3.3  2.7 vs. 1.8  2.6
in medically treated patients) may represent a bias
towards the selection of lower-risk patients, as
suggested by the relatively low rate of cardiac events
at 44 months in the overall population (4.5%).
However, one should note that medically treated
patients, included in the main outcome analysis,
had a relatively high-risk profile, with 52% of
patients with known CAD, an average number of 3
risk factors, and regional WMA at rest in 38.5%. At
the time of CMR acquisitions (between 2000 and
2004), DSMR was not widely accepted, and the
treatment option was not fully driven by the results
of CMR. Thus, the secondary analysis of the
outcome based on the treatment strategy and in-
cluding the 352 patients who underwent early
revascularization does not reflect an outcome that
was clearly driven by CMR data. Since the overallSafety and feasibility of high-dose dapaka S, et al. Prconceivable that the data in the 94 missing patients
might have impacted the main results. Those pa-
tients lost to follow-up had similar baseline charac-
teristics, but were slightly younger (57 12 vs. 61 10
years, p  0.001) and had a lower rate of inducible
WMA (17% vs. 40.7%; p 0.001). The distinction
was made throughout the paper between DSMR
with inducible WMA as opposed to “normal”
DSMR. It would be more appropriate to distin-
guish between DSMR with and without inducible
WMA, since a DSMR showing WMA at rest
without inducible WMA cannot be defined as a
normal test. The presence of late gadolinium en-
hancement (LGE) in patients with known or sus-
pected CAD is a strong and independent predictor
of adverse cardiac prognosis (11). The lack of LGE
imaging appears as a clear limitation of the study,
but the prognostic information provided by LGE
was not known at the time of the current study.
It seems clear that further studies combining
DSMR, perfusion imaging, and LGE may offer
additional prognostic information in those subjects
with suspected ischemia. This kind of comprehen-
sive protocol will have to be compatible with a
single CMR examination, which could soon be
possible with the continuous and impressive accel-
eration of CMR acquisitions. The possible addi-
tional value of DSMR tagging or strain-encoded
sequences over cine MR, using visual qualitative
analysis or fast-automated quantification algo-
rithms, is unknown and will have to be tested in
large-scale studies.
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